Some studies showed that phenybutyl isoselenocyanate (ISC-4) treatment significantly inhibited PI3K/AKT activation in a dose-dependent manner, and ISC-4-mediated p-Akt inhibition resulted in primary AML (CD34+) stem cell apoptosis and enhanced the efficacy of cytidine138. This evidence concerns the gene CD34 and acute myeloid leukemia.